1. Introduction {#sec1-genes-10-00715}
===============

Hereditary hearing loss affects approximately one in 500--600 infants in developed countries, and genetic causes account for at least 50% of all childhood hearing loss \[[@B1-genes-10-00715]\]. Approximately 100 genes have been recognized as causative for sensorineural hearing loss (SNHL) \[[@B2-genes-10-00715]\]. Next-generation sequencing (NGS) analysis has become a powerful tool for finding variants in many rare genes, and has allowed genetic epidemiology to be clarified \[[@B3-genes-10-00715],[@B4-genes-10-00715]\]. We have recently reported a series of studies on various relatively rare genes in the Japanese population, including *POU4F3* \[[@B5-genes-10-00715]\], *WFS1* \[[@B6-genes-10-00715]\], *OTOF* \[[@B7-genes-10-00715]\], and *STRC* \[[@B8-genes-10-00715]\]. The study was performed as one in a series of findings on specific genes that were published based on the same cohort.

In general, most of the causal mutations in these genes are small insertions/deletions (indels) or single nucleotide variants (SNVs). Recently, copy number variations (CNVs), that is, the alteration through deletion, insertion and/or duplication of more than 1 kbp, involving the genes associated with hearing loss have been observed in several patients with hearing loss (HL) \[[@B8-genes-10-00715],[@B9-genes-10-00715]\]. Shearer et al. reported that 143 CNVs were identified in 16 of 89 deafness-associated genes from 686 patients, with the greatest number of CNVs identified in the *STRC* and *OTOA* genes, comprising 73% and 13% of all identified CNVs, respectively \[[@B9-genes-10-00715]\].

The *OTOA* gene (Locus: DNFB22) was first reported as one of the responsible genes for non-syndromic autosomal recessive hearing loss by Zwaenepoel et al. in 2002 \[[@B10-genes-10-00715]\]. *OTOA* is located on chromosome 16p12.2, and encodes otoancorin, a protein required for limbal attachment of the tectorial membrane, which is important for conditioning proper stimulation of the inner hair cells \[[@B11-genes-10-00715],[@B12-genes-10-00715]\].

To date, 27 different variants \[[@B9-genes-10-00715],[@B10-genes-10-00715],[@B12-genes-10-00715],[@B13-genes-10-00715],[@B14-genes-10-00715],[@B15-genes-10-00715],[@B16-genes-10-00715],[@B17-genes-10-00715],[@B18-genes-10-00715],[@B19-genes-10-00715],[@B20-genes-10-00715],[@B21-genes-10-00715],[@B22-genes-10-00715]\] and 24 long or whole gene deletions \[[@B9-genes-10-00715],[@B13-genes-10-00715],[@B15-genes-10-00715],[@B16-genes-10-00715],[@B19-genes-10-00715],[@B20-genes-10-00715],[@B23-genes-10-00715],[@B24-genes-10-00715],[@B25-genes-10-00715]\] in the *OTOA* gene have been reported to cause SNHL in various ethnic groups, mainly in the Middle-Eastern countries. Although previous papers reported on the SNVs, indels, splicing variants, or CNVs, the detailed clinical characteristics of patients with *OTOA* variants still remain unclear.

In the present study, we aimed to clarify the prevalence and the clinical characteristics of *OTOA*-associated SNHL by using the NGS platform to identify small variants and CNVs in the *OTOA* gene, and confirmed their existence via direct sequencing or high-resolution array genomic hybridization (aCGH) analysis.

2. Materials and Methods {#sec2-genes-10-00715}
========================

2.1. Subjects {#sec2dot1-genes-10-00715}
-------------

This study was undertaken using data from a total of 2262 Japanese autosomal recessive sensorineural hearing loss (ARSNHL) probands (including sporadic cases) registered from 67 otorhinolaryngology departments in Japan between May 2013 and November 2018. The ages of the probands ranged from 0 to 86 years (mean 21.3 years). To participate in this study, written informed consent was obtained from all patients or the family members of the proband. All procedures were approved by the Shinshu University Ethical Committee as well as the respective ethical committees of the other participating institutions. All methods were in accordance with the Shinshu University Ethical Committee for Human Genetic Research guidelines and regulations.

This study was conducted in accordance with the Declaration of Helsinki, with the protocol approved by the Ethics Committee of Shinshu University School of Medicine No. 387-4 September 2012 and No. 576-2 May 2017.

2.2. Short Variant Analysis Including SNVs, Indels, and Splicing Variants {#sec2dot2-genes-10-00715}
-------------------------------------------------------------------------

We developed amplicon libraries, using an Ion AmpliSeq™ Custom Panel (ThermoFisher Scientific, Waltham, MA, USA), for 68 genes previously reported as genetic causes of non-syndromic hearing loss ([Supplementary Table S1](#app1-genes-10-00715){ref-type="app"}), and performed emulsion PCR and sequencing, in line with the manufacturer's instructions. The detailed procedures have been described in our published paper \[[@B26-genes-10-00715]\]. NGS was performed with an Ion Torrent Personal Genome Machine (PGM) system using an Ion PGM 200 Sequencing Kit and an Ion 318 Chip (ThermoFisher Scientific) or Ion Proton™ system using the Ion PI™ HiQ™ Sequencing 200 Kit and Ion PI™ Chip (ThermoFisher Scientific). We mapped the sequence data against the human genome sequence (build GRCh37/hg19) with a Torrent Mapping Alignment Program. After sequence mapping, the DNA variant regions were stacked with Torrent Variant Caller plug-in software. After variant detection, we analyzed their effects using ANNOVAR software \[[@B27-genes-10-00715]\]. The variants (missense, nonsense, insertion/deletion and splicing variants) affecting the amino acid sequence were selected from among the identified variants. Variants were further selected as less than 1% of (1) the ExAC \[[@B28-genes-10-00715]\], (2) gnomAD \[[@B29-genes-10-00715]\], (3) 3.5KJPN \[[@B30-genes-10-00715]\] databases, and (4) the 333 in-house Japanese normal hearing controls. We employed direct sequencing to confirm the selected variants.

The pathogenicity of a variant was evaluated based on the criteria of the ACMG (American College of Medical Genetics) standards and guidelines \[[@B31-genes-10-00715]\]. For missense variants, in particular, functional prediction software, including Sorting Intolerant from Tolerant (SIFT) \[[@B32-genes-10-00715]\], Polymorphism Phenotyping (PolyPhen2) \[[@B33-genes-10-00715]\], Likelihood Ratio Test (LRT) \[[@B34-genes-10-00715]\], Mutation Taster \[[@B35-genes-10-00715]\], Mutation Assessor \[[@B36-genes-10-00715]\], Rare Exome Variant Ensemble Learner (REVEL) \[[@B37-genes-10-00715]\], and Combined Annotation Dependent Depletion (CADD) \[[@B38-genes-10-00715]\] were used on the ANNOVAR software. We also evaluated the conservation of the variant site in 170 vertebrates from HGMD Professional. \[[@B39-genes-10-00715]\]. Segregation analysis was performed for each proband and family members (if samples were obtained or available) by direct sequencing.

2.3. Copy Number Variations (CNVs) Analysis {#sec2dot3-genes-10-00715}
-------------------------------------------

We performed a CNV detection method with Ion AmpliSeq sequencing and multiplex PCR-based targeted genome enrichment. The detailed protocol has been described elsewhere \[[@B40-genes-10-00715]\]. The read depth data was used for copy number analysis. From the results of the CNVs analysis of the 2262 probands, we picked up 14 patients with *OTOA* gene CNVs.

We designed a custom aCGH for 68 genes previously reported as genetic causes of non-syndromic hearing loss using the Agilent web software (Agilent SureDesign, Agilent Technologies, Santa Clara, CA, USA), with the probes covering specific chromosomal regions of those genes at 150--200 bp intervals as a design-setting on the Agilent 8 × 60 K platform (Agilent Technologies, Santa Clara, CA, USA) \[[@B41-genes-10-00715]\]. There were 235 probes laid across the *OTOA* region (chr16:21,740,000--21,772,500). We used the same DNA samples as used for the amplicon resequencing, with quality assessment also performed. Five micrograms of genomic DNA were fragmented, and labeled with cyanine-3 for reference DNA samples and cyanine-5 for subjects, and then hybridized. We performed scanning of the array with a G2600D SureScan Microarray Scanner (Agilent Technologies) according to the manufacturer's recommended protocols, and analyzed scanned aCGH data using CytoGenomics software version 3.0.6.6 (Agilent Technologies).

2.4. Clinical Evaluations {#sec2dot4-genes-10-00715}
-------------------------

Clinical information including the age of onset of SNHL, the result of newborn hearing screening (NHS), pedigree, the presence of subjective progression in SNHL, and episodes of vertigo/dizziness were collected from each proband from a review of the medical charts.

Hearing loss was evaluated using pure-tone audiometry and severity of SNHL was classified by a pure-tone average (PTA) over 500, 1000, 2000 and 4000 Hz. If an individual did not respond to the maximum hearing level at a frequency, 5 dB was added to the maximum hearing level. The severity of HL was classified as follows: mild (PTA: 20--40 dB HL), moderate (41--70 dB HL), severe (71--95 dB HL), and profound (\>95 dB HL). Audiometric configuration was categorized into low-frequency, mid-frequency (U-shaped), high-frequency (gently or steeply sloping), or flat based on a previous report \[[@B42-genes-10-00715]\].

3. Results {#sec3-genes-10-00715}
==========

3.1. Identified OTOA Variants and Their Prevalence in Japanese ARSNHL Patients {#sec3dot1-genes-10-00715}
------------------------------------------------------------------------------

Of 2262 cases, CNVs in the 68 target genes were detected in 234 cases (10.3%, 234/2262). The most frequent gene with CNVs was the *STRC* gene (8.4%, 190/2262), followed by the *OTOA* gene (0.6%, 14/2262). Among the 14 cases with *OTOA* gene CNVs, two carried homozygous deletions, nine carried heterozygous deletions, and three carried three copies (one-copy gain). Among the nine cases with heterozygous deletions in the *OTOA* gene, four cases have possibly disease-causing small variants of the *OTOA* gene in the other allele. Additionally, we identified one case with *OTOA* gene homozygous SNVs. Finally, we identified seven probands with *OTOA*-associated HL in this study ([Table 1](#genes-10-00715-t001){ref-type="table"}). Thus, the prevalence of OTOA-associated HL in Japanese ARSNHL patients was calculated to be 0.3% (7/2262). All were sporadic cases, and there were no affected family members ([Figure 1](#genes-10-00715-f001){ref-type="fig"}). No candidate pathogenic variants in the other 67 deafness genes were detected in these seven individuals. Unfortunately, we could not obtain un-affected sibling samples as shown in [Figure 1](#genes-10-00715-f001){ref-type="fig"}. Thus, the segregation analysis was not performed for these families.

3.2. Confirmation of CNVs and Short Variants, and The Pathogenic Interpretation of These Variants {#sec3dot2-genes-10-00715}
-------------------------------------------------------------------------------------------------

In this study, we detected CNVs by using NGS read data as a first screening step followed by confirmation with aCGH. We performed aCGH analysis to confirm the CNVs for five individuals. Two of them (HL5890 and HL5771) carried homozygous deletions in the *OTOA* gene and three (HL5722, HL5367, and HL6578) carried heterozygous deletions. All cases had entire *OTOA* gene deletions, and the aCGH results were consistent with the NGS-based analysis results. Furthermore, deletions in all cases included the *METTL9* and *IGSF6* genes, which are located upstream of the *OTOA* gene. [Figure 2](#genes-10-00715-f002){ref-type="fig"} shows the results of NGS analysis and aCGH analysis in these cases. We also performed aCGH analysis for a case with three copies as a technical confirmation, and the results were consistent with the NGS analysis results. Therefore, we believe that CNV analysis using NGS data is reliable, even for heterozygous deletions, homozygous deletions, and one-copy gains in the *OTOA* gene. Unfortunately, the total amount of DNA available for HL0511 was not sufficient for aCGH analysis, so we did not perform aCGH analysis for this patient.

All five single nucleotide variants (c.235C\>T, c.442C\>T, c.469C\>T, c.1705A\>G, and c.647T\>C) identified in this study were evaluated according to the ACMG standards and guidelines \[[@B31-genes-10-00715]\]. All variants were novel, and were not observed or observed in very low frequency in the control population database (PM2) ([Table 2](#genes-10-00715-t002){ref-type="table"}). One mutation (c.442C\>T) was categorized as a "likely pathogenic" variant as this variant is a nonsense variant (p.(Asp148^\*^)) leading to the stop codon (PVS1). Three missense variants (c.235C\>T, c.469C\>T, and c.1705A\>G) detected in *trans* with a pathogenic (whole gene deletion) variant (PM3) were categorized as being of "uncertain significance". The remaining missense variant identified as homozygous (c.647T\>C) was also categorized as of "uncertain significance". All four missense variants were predicted as deleterious and have high CADD scores.

3.3. Clinical Features of OTOA-Associated SNHL Patients {#sec3dot3-genes-10-00715}
-------------------------------------------------------

[Table 1](#genes-10-00715-t001){ref-type="table"} summarizes the clinical findings of the seven affected individuals identified in this study. The age of onset of HL ranged from congenital to childhood. All congenital cases were identified through NHS, but the other childhood onset cases did not receive NHS. Most of the cases have bilateral symmetrical SNHL ([Figure 1](#genes-10-00715-f001){ref-type="fig"}), and the severity of HL ranged from moderate to severe. Interestingly, most cases showed mid-frequency HL. Based on the audiometric configuration classification criteria previously reported, mid-frequency HL was observed in nine ears, flat type in three ears, and high-frequency HL in two ears. Progression of HL was noticed, based on the medical charts, for three (all adults: HL5890, HL0511, and HL5367) of the seven individuals. Serial audiograms could be obtained from one individual (HL5367), and the averaged hearing threshold (PTA) was observed to have slowly deteriorated from 41.25 dB at 4 years old to 55 dB at 19 years old. Vertigo/dizziness is rare among patients with *OTOA*-associated HL, and only one individual (HL5890) was found to have episodes of vertigo.

4. Discussion {#sec4-genes-10-00715}
=============

In our cohort of 2262 Japanese ARSNHL patients, we identified seven probands with *OTOA*-associated HL, including two cases with homozygous deletions, four cases with heterozygous deletions in *trans* to a SNVs, and one case with homozygous SNVs. The frequency of *OTOA*-associated HL in Japanese ARSNHL patients was calculated to be 0.3% (7/2262). In a previous report analyzing a larger number of patients, Shearer et al. identified five probands with *OTOA*-associated HL among 686 SNHL patients from American probands, so that the frequency of *OTOA*-associated HL was calculated to be 0.7% among all SNHL patients (5/686) \[[@B9-genes-10-00715]\]. Sloan-Heggen et al. identified eight probands with *OTOA*-associated HL among 1119 unrelated SNHL patients from various ethnic populations (0.7%) \[[@B16-genes-10-00715]\] and also identified six *OTOA*-associated HL cases among 302 Iranian patients (2.0%) \[[@B13-genes-10-00715]\]. Our results were comparable with the studies on both the American patients and various ethnic populations, but noticeably lower than that on the Iranian patients. These differences may reflect differences in the ratio of consanguineous patients among each cohort.

To elucidate the prevalence of *OTOA* CNVs in the normal hearing population, we also performed NGS analysis for 152 normal hearing controls (data not shown). The controls were aged from 20--30 years, and pure-tone audiometry was performed for each control, showing normal hearing. Among the 152 controls, none carried a copy number loss of the *OTOA* gene, but one case carried three copies of the *OTOA* gene. It was unclear whether the one-copy gain of the *OTOA* gene was pathogenic or neutral (no impact on phenotype). However, the identification of a one-copy gain of the *OTOA* gene from a control case, suggests that this one-copy gain of the *OTOA* gene was not associated with any phenotypes. Therefore, the CNVs of *OTOA* were rare in Japanese control population.

For all *OTOA* gene CNVs identified in this study, the aCGH results showed that the whole *OTOA* gene as well as whole *METTL9* and *IGSF6* genes were deleted or duplicated. In the previous three reports analyzing the deletion region in detail \[[@B23-genes-10-00715],[@B24-genes-10-00715],[@B43-genes-10-00715]\], all cases carried a whole *OTOA*, *METTL9* and *IGSF6* gene deletion as in this study. One plausible reason for relatively large number of CNVs observed in this area and same types of deletion including *OTOA*, *METTL9,* and *IGSF6* were observed even in different ethnic population, is the segmental duplications of the region in chromosome 16p12.2. There is a highly homologous sequences before and after chr16p12.2, including the *OTOA*, *METTL9,* and *IGSF6* genes \[[@B23-genes-10-00715],[@B43-genes-10-00715],[@B44-genes-10-00715],[@B45-genes-10-00715]\]. Further, these segmental duplication increased mis-homologous recombination in this region, and may act as a hotspot for CNVs. As a result of this mis-homologous recombination, the similar CNVs in this area (including the *OTOA*, *METTL9,* and *IGSF6* genes) may be commonly observed in many ethnic populations.

The *OTOA* gene has a pseudogene located 820Kb downstream, which has a high sequence similarity and 99% or more homology in the exon 20--28 region of the *OTOA* gene \[[@B23-genes-10-00715]\]. Therefore, the mapping quality of this region was degraded and SNV detection in this region is challenging when using short-read NGS \[[@B46-genes-10-00715]\]. Except for one variant (c.2960_2961delAT), all variants identified in this study and previous studies were located in exon 3-19 (summarized in [Table 3](#genes-10-00715-t003){ref-type="table"}).

In this study, we identified nine cases with one-copy loss of the *OTOA* gene. Among these nine cases, four cases carried one-copy loss of the OTOA gene with candidate SNVs in the *trans* allele; however, five cases carried only one-copy loss of the *OTOA* gene. Shearer et al. also reported five cases among 686 cases that carried one-copy loss of the *OTOA* gene without any other SNVs in the *OTOA* gene \[[@B4-genes-10-00715]\]. Among these cases, there might be some cases with SNVs in the exon 20--28 region that cause *OTOA*-associated HL. To confirm these cases, newer technologies such as long-read NGS are required.

In this study, we used aCGH to confirm the CNVs identified from NGS results. Array CGH has been the gold standard for copy number analysis, but it is time-consuming and costly. Thus, now we employ NGS as the standard CNVs analysis method as it is possible to detect the SNVs and CNVs in one experiment \[[@B15-genes-10-00715]\]. In addition, we are currently trying to establish a social health insurance-based platform using NGS as standard CNV detection method as it is possible to detect SNVs and CNVs at the same time and it is more cost- and time-effective.

The severity of the *OTOA*-associated HL varied from moderate to severe, but most of the cases showed moderate HL (86%, 6/7 individuals) in this study. Also in previous reports, the severity of HL varied significantly from mild to profound (summarized in [Table 4](#genes-10-00715-t004){ref-type="table"}). Even in cases of homozygous *OTOA* gene deletions, significant differences were observed in the severity of HL. These differences in the severity of HL may be due to other environmental or genetic factors including aging. The progress of HL in patients with *OTOA*-associated HL has not been specifically described in previous reports. In the present study, three adult cases noticed progression of HL, and the progression was confirmed by serial audiograms in one patient in whom the averaged hearing threshold (PTA) was slowly deteriorated from 41.25 dB at 4 years old to 55 dB at 19 years old. From these observations, progressive HL appears to be a common trend in *OTOA*-associated HL. With regard to the age of onset, three cases showed congenital HL and others showed prelingual to childhood onset in this study. In previous reports, the age of onset was pre-childhood in most cases, but two cases of adult onset were reported \[[@B9-genes-10-00715],[@B16-genes-10-00715]\]. All three cases with congenital HL identified in this study were identified through NHS screening. Thus, we estimated that most cases of *OTOA*-associated HL may be congenital and could be identified through NHS screening. However, in cases not undergoing such screening, the HL was mild to moderate and progressed slowly, and was identified in childhood or later.

It is noteworthy that mid-frequency HL was most commonly observed in individuals with *OTOA* variants in this study. In addition, flat HL and high-frequency HL were also observed in some cases. In previous reports, only Alkowari et al. have provided detailed audiograms of the three cases from one family with homozygous *OTOA* deletions, and the audiometric configurations of these patients were mid-frequency HL \[[@B25-genes-10-00715]\]. Interestingly, otoancorin, encoded by the *OTOA* gene, is a protein that acts as a glycosylphosphatidylinositol (GPI) anchorage, and is important for limbal attachment of the tectorial membrane (TM) \[[@B11-genes-10-00715],[@B12-genes-10-00715]\]. The *TECTA* gene (Locus: DFNA8/12) encoding α-tectorin, a major non-collagenous glycoprotein of TM, which is expressed in the spiral limbus during TM development \[[@B10-genes-10-00715],[@B11-genes-10-00715]\], is also known as a genetic cause of mid-frequency HL \[[@B47-genes-10-00715],[@B48-genes-10-00715],[@B49-genes-10-00715]\]. The similarities between the clinical characteristics of HL in patients with *OTOA* and *TECTA* gene mutations reflect the mechanism of deafness caused by TM impairment. The results of this study will be useful for the selection of more appropriate treatment for patients as well as the further understanding of the disease-causing mechanisms of *OTOA*-associated HL.

5. Conclusions {#sec5-genes-10-00715}
==============

Here, we presented the detailed clinical characteristics of the seven patients with *OTOA*-associated HL identified from 2262 unrelated Japanese ARNSHL patients. The prevalence of *OTOA*-associated HL in Japanese ARSNHL patients was calculated to be 0.3%. This is the first report of HL caused by this gene mutation in Japanese patients with HL. The remarkable clinical characteristics of the patients with *OTOA* variants was congenital or early onset, progressive, mid-frequency HL.
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The following are available online at <https://www.mdpi.com/2073-4425/10/9/715/s1>, Table S1: 68 deafness-causative genes.
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![Pedigree and audiograms for each family with *OTOA* variants. Arrows show the probands in each family. The ages indicated in the pedigree represent the time at which the audiogram was obtained. Genetic findings for each individual tested are also noted in the pedigree.](genes-10-00715-g001){#genes-10-00715-f001}

![The results of copy number variation (CNV) analysis. (**A**) The results of CNV analysis based on next-generation sequencing (NGS) read depth data for patients with two-copy loss (homozygous deletion), one-copy loss (heterozygous deletion), or one-copy gain (three copies) in the *OTOA* gene identified in the present study. (**B**) The results of aCGH analysis for the same patients. Black arrows indicate the *OTOA* region. Red arrows indicate deletions, and blue arrows indicate duplications.](genes-10-00715-g002){#genes-10-00715-f002}

genes-10-00715-t001_Table 1

###### 

Summary of the clinical features and identified variants of individuals with *OTOA* variants in this study.

                                                                                                                     Newborn       Average             Audiometric   Hearing       
  -------- ----------------- --------------------- --------------- --------------------- --------------- ----------- ------------- ------------- ----- ------------- ------------- ----
  HL5771   homo              whole gene deletion                   whole gene deletion                   3y          N/A           58.75/62.5    4y    MF/MF                       \-
  HL5890   homo              whole gene deletion                   whole gene deletion                   childhood   N/A           77.5/72.5     69y   Flat/MF       progressive   \+
  HL0511   compound hetero   whole gene deletion                   c.235C\>T             p.(Arg79Trp)    7y          N/A           56.25/55      30y   HF/MF         progressive   \-
  HL5722   compound hetero   whole gene deletion                   c.442C\>T             p.(Arg148\*)    0m          refer/refer   58.75/76.25   7y    Flat/HF                     \-
  HL5367   compound hetero   whole gene deletion                   c.469C\>T             p.(Arg157Cys)   5y          N/A           55/57.5       19y   MF/MF         progressive   \-
  HL6578   compound hetero   whole gene deletion                   c.1705A\>G            p.(Lys569Glu)   0m          refer/refer   46.25/42.5    4y    MF/MF                       \-
  HL4132   homo              c.647T\>C             p.(Phe216Ser)   c.647T\>C             p.(Phe216Ser)   0m          refer/refer   62.5/68.75    5y    Flat/MF                     \-

All variants were indicated in NM_144672. y: year(s), m: month(s), N/A: not applicable (not received NHS), HF: high-frequency sensorineural hearing loss, MF: mid-frequency sensorineural hearing loss.

genes-10-00715-t002_Table 2

###### 

Possible causative variant identified in this study.

                                Prediction Score   Allele Frequency in Controls                                                                                                            
  ------------ ---------------- ------------------ ------------------------------ ---------- ---------- ---------- ------- ------ ------------ ------------ ----- ------------------------ -----------
  c.235C\>T    p.(Arg79Trp)     D(0.4)             B(0.166)                       N(0.132)   N(0.09)    M(0.552)   0.21    23.6   0.00000824   0.00000812   N/A   Uncertain Significance   PM2,PM3
  c.442C\>T    p.(Arg148\*)     \-                 \-                             N(0.225)   A(0.81)    \-         \-      35     0.0000247    0.0000163    N/A   Likely Pathogenic        PVS1, PM2
  c.469C\>T    p.(Arg157Cys)    D(0.912)           D(0.916)                       D(0.629)   D(0.548)   M(0.752)   0.285   34     0.0000165    0.0000203    N/A   Uncertain Significance   PM2,PM3
  c.1705A\>G   p.(Lys569Glu)    D(0.427)           D(0.875)                       D(0.629)   D(0.441)   M(0.567)   0.598   31     N/A          N/A          N/A   Uncertain Significance   PM2,PM3
  c.647T\>C    p.(Phe 216Ser)   D(0.721)           D(0.764)                       D(0.629)   D(0.412)   M(0.741)   0.326   24.3   N/A          N/A          N/A   Uncertain Significance   PM2

\* The Prediction Score of each algorithm included in the ANNOVAR software was converted from the original scoring system. A score closer to 1.0 indicated the variant was predicted to be more damaging. A, disease causing automatic (Mutation Taster); B, benign (PolyPhen2_HVAR); D, deleterious (SIFT, LRT), probably damaging (PolyPhen2), or disease causing (Mutation Taster); M, medium (Mutation Assessor); N, Neutral (LRT). PVS: evidence of Pathogenicity---Very Strong, PM: evidence of Pathogenicity---Moderate.

genes-10-00715-t003_Table 3

###### 

Summary of variants identified in this and previous studies (NM_144672).

                                                   Allele Frequency   Prediction Score                                                                          
  --------------------------- --------------- ---- ------------------ ------------------ ---------- ---------- ---------- ---------- ---------- ------- ------- -------------------------------------------------------------------------------------------------------------------------------------------
  missense/nonsense variant                                                                                                                                     
  c.131T\>C                   p.(Ile44Thr)    3    0.0000494          0.0000731          D          P          D          D          M          N/A     23.8    Christina M. Sloan-Heggen, 2016 \[[@B16-genes-10-00715]\]
  c.235C\>T                   p.(Arg79Trp)    5    0.00000824         0.00000812         D(0.4)     B(0.166)   N(0.132)   N(0.09)    M(0.552)   0.21    23.6    this study
  c.313A\>T                   p.(Lys105\*)    6    N/A                N/A                \-         \-         \-         \-         \-         \-      \-      Christina M. Sloan-Heggen, 2016 \[[@B16-genes-10-00715]\]
  c.442C\>T                   p.(Arg148\*)    7    0.0000247          0.0000163          \-         \-         N(0.225)   A(0.81)    \-         \-      35      this study
  c.446C\>A                   p.(Ala149Asp)   7    0.000016           N/A                D          D          N          P          \-         \-      28.8    Shearer, 2014 \[[@B9-genes-10-00715]\]
  c.469C\>T                   p.(Arg157Cys)   7    0.0000165          0.0000203          D(0.912)   D(0.916)   D(0.629)   D(0.548)   M(0.752)   0.285   34      this study
  c.647T\>C                   p.(Phe216Ser)   8    N/A                N/A                D(0.721)   D(0.764)   D(0.629)   D(0.412)   M(0.741)   0.326   24.3    this study
  c.878A\>G                   p.(Gln293Arg)   10   N/A                N/A                D          P          D          D          M          \-      24.2    L. He, 2018 \[[@B17-genes-10-00715]\]
  c.1025A\>T                  p.(Asp342Val)   11   N/A                N/A                D(0.784)   D(0.719)   N(0.388)   D(0.81)    M(0.552)   0.453   26.7    Walsh, 2006 \[[@B18-genes-10-00715]\]
  c.1249C\>T                  p.(Leu417Phe)   12   0.0000165          0.0000163          D          P          D          D          M          \-      28.6    Tsai, 2013 \[[@B19-genes-10-00715]\]
  c.1282G\>T                  p.(Val428Phe)   12   N/A                N/A                D          P          N          P          L          \-      24.7    Cabanillas, 2018 \[[@B20-genes-10-00715]\]
  c.1352G\>A                  p.(Gly451Asp)   13   0.00000824         0.00000407         D(0.912)   D(0.971)   D(0.439)   D(0.524)   M(0.567)   0.768   24.8    K Lee, 2013 \[[@B21-genes-10-00715]\]
  c.1705A\>G                  p.(Lys569Glu)   16   N/A                N/A                D(0.427)   D(0.875)   D(0.629)   D(0.441)   M(0.567)   0.598   31      this study
  c.1728T\>G                  p.(Ile576Met)   16   0.000033           0.0000284          D          P          D          D          M          \-      23.8    Christina M. Sloan-Heggen, 2016 \[[@B16-genes-10-00715]\]
  c.1865T\>A                  p.(Leu622His)   17   0.000008           N/A                D          P          D          D          \-         \-      29.1    P Fontana, 2017 \[[@B15-genes-10-00715]\]
  c.1807G\>T                  p.(Val603Phe)   16   N/A                0.00000406         T          P          N          D          M          \-      26.6    Ammar-Khodja, 2015 \[[@B22-genes-10-00715]\]; Christina M. Sloan-Heggen, 2016 \[[@B16-genes-10-00715]\]
  c.1814G\>C                  p.(Cys605Ser)   17   N/A                N/A                T          P          D          D          M          \-      26.8    Christina M. Sloan-Heggen, 2016 \[[@B16-genes-10-00715]\]
  c.1879C\>T                  p.(Pro627Ser)   17   0.000033           0.0000366          D(0.496)   D(0.916)   D(0.629)   D(0.548)   M(0.567)   0.446   31      K Lee, 2013 \[[@B21-genes-10-00715]\]; Christina M. Sloan-Heggen, 2015 \[[@B13-genes-10-00715]\]
  c.1939G \> C                p.(Gly647Arg)   18   N/A                0.0000122          T(0.363)   P(0.604)   D(0.629)   D(0.478)   M(0.567)   0.813   23.6    Christina M. Sloan-Heggen, 2015 \[[@B13-genes-10-00715]\]
  c.2201A\>G                  p.(Gln734Arg)   19   0.00000824         0.00000407         T(0.330)   B(0.339)   N(0.229)   D(0.330)   M(0.723)   0.079   8.163   Christina M. Sloan-Heggen, 2015 \[[@B13-genes-10-00715]\]
  splicing variant                                                                                                                                              
  c.151+1G\>A                                      N/A                N/A                \-         \-         \-         D(0.81)    \-         \-      26.3    Christina M. Sloan-Heggen, 2015 \[[@B13-genes-10-00715]\]
  c.1320+2T\>C                                     N/A                N/A                \-         \-         \-         D(0.81)    \-         \-      24.2    Zwaenepoel, 2002 \[[@B10-genes-10-00715]\]
  c.1320+5G\>C                                     N/A                0.00001            \-         \-         \-         D          \-         \-      21.7    Bong Jik Kim, 2019 \[[@B12-genes-10-00715]\]
  c.2208−1G\>A                                     0.000036           N/A                \-         \-         \-         D(0.81)    \-         \-      22.4    Christina M. Sloan-Heggen, 2015 \[[@B13-genes-10-00715]\]
  small deletion                                                                                                                                                
  c.827delT                   p.(Ile276fs)    9    0.000025           N/A                \-         \-         \-         N/A        \-         \-      35      Shearer, 2014 \[[@B9-genes-10-00715]\]; Christina M. Sloan-Heggen, 2016 \[[@B16-genes-10-00715]\]; Sommen, 2016 \[[@B14-genes-10-00715]\]
  c.1765delC                  p.(Gln589fs)    17   0.000025           N/A                \-         \-         \-         D          \-         \-      28.5    Bong Jik Kim, 2019 \[[@B12-genes-10-00715]\]
  c.2960_2961delAT            p.(His987fs)    25   0.000094           N/A                \-         \-         \-         N/A        \-         \-      25.3    Sommen, 2016 \[[@B14-genes-10-00715]\]

All variants were indicated in NM_144672. \* The Prediction Score of each algorithm included in the ANNOVAR software was converted from the original scoring system. A score closer to 1.0 indicated the mutation was more damaging, and that closer to 0 indicated it was more tolerant. A disease causing automatic (Mutation Taster); B, benign (PolyPhen2); D, deleterious (SIFT, LRT), probably damaging (PolyPhen2), or disease causing (Mutation Taster); L, low (Mutation Assessor); M, medium (Mutation Assessor); N, Neutral (LRT), polymorphism (Mutation Taster); P, possibly damaging (PolyPhen2), polymorphism automatic (Mutation Taster); T, Tolerated (SIFT).
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###### 

Summary of clinical features associated with *OTOA* variants from this and previous studies.

  Hereditary   Onset            Average hearing level           Zygosity          Allele \#1                            Allele \#2                            Reference
  ------------ ---------------- ------------------------------- ----------------- --------------------- --------------- --------------------- --------------- -----------------------------------------------------------
  AR/Spo       3y               moderate                        homo              whole gene deletion                   whole gene deletion                   this study
  AR/Spo       childhood        severe                          homo              whole gene deletion                   whole gene deletion                   this study
  AR           prelingual       N/A                             homo              whole gene deletion                   whole gene deletion                   Shahin, 2010 \[[@B23-genes-10-00715]\]
  AR           N/A              mild to moderate                homo              whole gene deletion                   whole gene deletion                   Bademci, 2014 \[[@B24-genes-10-00715]\]
  AR           0−10y            moderate to severe              homo              Whole gene deletion                   whole gene deletion                   Shearer, 2014 \[[@B9-genes-10-00715]\]
  N/A          21−30y           N/A                             homo              whole gene deletion                   whole gene deletion                   Shearer, 2014 \[[@B9-genes-10-00715]\]
  AR           prelingual       moderate to severe              homo              whole gene deletion                   whole gene deletion                   Christina M. Sloan-Heggen, 2015 \[[@B13-genes-10-00715]\]
  N/A          N/A              N/A                             homo              whole gene deletion                   whole gene deletion                   Christina M. Sloan-Heggen, 2016 \[[@B16-genes-10-00715]\]
  AD           adult            severe to profound              homo              whole gene deletion                   whole gene deletion                   Christina M. Sloan-Heggen, 2016 \[[@B16-genes-10-00715]\]
  Spo          congenital       severe to profound              homo              whole gene deletion                   whole gene deletion                   Christina M. Sloan-Heggen, 2016 \[[@B16-genes-10-00715]\]
  AR           1−13y            severe                          homo              58000bp deletion                      58000bp deletion                      Alkowari, 2017 \[[@B25-genes-10-00715]\]
  AR           prelingual       severe                          homo              c.151+1G\>A                           c.151+1G\>A                           Christina M. Sloan-Heggen, 2015 \[[@B13-genes-10-00715]\]
  AR/Spo       0m               moderate                        homo              c.647T\>C             p.(Phe216Ser)   c.647T\>C             p.(Phe216Ser)   this study
  AR           prelingual       moderate to severe              homo              c.1025A\>T            p.(Asp342val)   c.1025A\>T            p.(Asp342val)   Walsh, 2006 \[[@B18-genes-10-00715]\]
  AR           prelingual       moderate to severe              homo              c1320+2T\>C                           c.1320+2T\>C                          Zwaenepoel, 2002 \[[@B10-genes-10-00715]\]
  AR           prelingual       severe                          homo              c.1352G\>A            p.(Gly451Asp)   c.1352G\>A            p.(Gly451Asp)   K Lee, 2013 \[[@B21-genes-10-00715]\]
  AR           prelingual       severe to profound              homo              c.1807G\>T            p.(Val603Phe)   c.1807G\>T            p.(Val603Phe)   Ammar-Khodja, 2015 \[[@B22-genes-10-00715]\]
  AR           prelingual       severe                          homo              c.1879C\>T            p.(Pro627Ser)   c.1879C\>T            p.(Pro627Ser)   K Lee, 2013 \[[@B21-genes-10-00715]\]
  AR           prelingual       moderate to severe              homo              c.1879C\>T            p.(Pro627Ser)   c.1879C\>T            p.(Pro627Ser)   Christina M. Sloan-Heggen, 2015 \[[@B13-genes-10-00715]\]
  AR           prelingual       moderate to severe              homo              c.1939G C             p.(Gly647Arg)   c.1939G\>C            p.(Gly647Arg)   Christina M. Sloan-Heggen, 2015 \[[@B13-genes-10-00715]\]
  AR           prelingual       moderately severe to profound   homo              c.2201A\>G            p.(Gln734Arg)   c.2201A\>G            p.(Gln734Arg)   Christina M. Sloan-Heggen, 2015 \[[@B13-genes-10-00715]\]
  AR/Spo       7y               moderate                        compound hetero   whole gene deletion                   c.235C\>T             p.(Arg79Trp)    this study
  N/A          0−10y            N/A                             compound hetero   whole gene deletion                   c.446C\>A             p.(Ala149Asp)   Shearer, 2014 \[[@B9-genes-10-00715]\]
  AR/Spo       5y               moderate                        compound hetero   whole gene deletion                   c.469C\>T             p.(Arg157Cys)   this study
  N/A          0−10y            N/A                             compound hetero   whole gene deletion                   c.827delT             p.(Ile276fs)    Shearer, 2014 \[[@B9-genes-10-00715]\]
  Spo          congenital       N/A                             compound hetero   whole gene deletion                   c.827delT             p.(Ile276fs)    Christina M. Sloan-Heggen, 2016 \[[@B16-genes-10-00715]\]
  AR           childhood        N/A                             compound hetero   whole gene deletion                   c.1282G\>T            p.(Val428Phe)   Cabanillas, 2018 \[[@B20-genes-10-00715]\]
  AD           congenital       N/A                             compound hetero   whole gene deletion                   c.1728T\>G            p.(Ile576Met)   Christina M. Sloan-Heggen, 2016 \[[@B16-genes-10-00715]\]
  AR/Spo       congenital       moderate                        compound hetero   whole gene deletion                   c.1705A\>G            p.(Lys569Glu)   this study
  Spo          childhood        severe to profound              compound hetero   whole gene deletion                   c.1807G\>T            p.(Val603Phe)   Christina M. Sloan-Heggen, 2016 \[[@B16-genes-10-00715]\]
  Spo          congenital       mild to moderate                compound hetero   whole gene deletion                   c.1814G\>C            p.(Cys605Ser)   Christina M. Sloan-Heggen, 2016 \[[@B16-genes-10-00715]\]
  AR           prelingual       severe                          compound hetero   whole gene deletion                   c.1865T\>A            p.(Leu622His)   P Fontana, 2017 \[[@B15-genes-10-00715]\]
  N/A          N/A              N/A                             compound hetero   multi exon deletion                   c.1249C\>T            p.(Leu417Phe)   Tsai, 2013 \[[@B19-genes-10-00715]\]t
  AR/Spo       0m               moderate                        compound hetero   deletion                              c.442C\>T             p.(Arg148\*)    this study
  AR           prelingual       N/A                             compound hetero   deletion                              c.2960_2961delAT      p.His987fs      Sommen, 2016 \[[@B14-genes-10-00715]\]
  Spo          before 6 years   moderate                        compound hetero   micro deletion                        c.878A\>G             p.(Gln293Arg)   L. He, 2018 \[[@B17-genes-10-00715]\]
  Spo          congenital       mild to moderate                compound hetero   c.131T\>C             p.(Ile44Thr)    c.313A\>T             p.(Lys105\*)    Christina M. Sloan-Heggen, 2016 \[[@B16-genes-10-00715]\]
  AR           prelingual       N/A                             compound hetero   c.827delT             p.(Ile276fs)    c.2960_2961delAT      p.(His987fs)    Sommen, 2016 \[[@B14-genes-10-00715]\]
  AR           congenital       moderate                        compound hetero   c.1320+5G\>C                          c.1765delC            p.(Gln589fs)    Bong Jik Kim, 2019 \[[@B12-genes-10-00715]\]

AD: autosomal dominant. AR: autosomal recessive. Spo: sporadic. N/A: not available. y: year(s), m: month(s).
